T. Rowe Price Investment Management
PTCT icon

T. Rowe Price Investment Management’s PTC Therapeutics PTCT Stock Holding History

T. Rowe Price Investment Management’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-174,088
Closed -$8.87M – 723
2025
Q1 		$8.87M Buy
+174,088
New +$8.69M 0.01% 564
2022
Q4 		– Sell
-248,299
Closed -$12.5M – 562
2022
Q3 		$12.5M Buy
+248,299
New +$12.2M 0.01% 487

Other funds holding PTCT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Investment Management's PTCT Position: Q2 2025 in Review

T. Rowe Price Investment Management sold out of PTC Therapeutics (PTCT) in Q2 2025, closing a stake of 174,088 shares — an estimated $8.87M sold.

T. Rowe Price Investment Management first reported a position in PTCT in Q3 2022 and held it in 2 quarters. The position peaked at $12.5M in Q3 2022. 284 funds tracked by Wall St. Rank hold PTCT as of Q2 2025.

  • T. Rowe Price Investment Management reported no remaining PTC Therapeutics position as of Q2 2025 after selling out during the quarter.
  • T. Rowe Price Investment Management sold 174,088 PTC Therapeutics shares in Q2 2025, an estimated $8.87M.
  • T. Rowe Price Investment Management first reported a position in PTC Therapeutics in Q3 2022 and held it in 2 quarters.
  • T. Rowe Price Investment Management's PTC Therapeutics position peaked at $12.5M in Q3 2022.
  • 284 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2025.

Based on T. Rowe Price Investment Management's 13F filing for Q2 2025, filed 14 Aug 2025.